Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review

Kristin E. Mondy, Bruce Haughey, Philip L. Custer, Franz J. Wippold, David J. Ritchie, Linda M. Mundy

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Rhinocerebral mucormycosis (RCM) is an invasive fungal infection that necessitates, in most cases, aggressive surgical debridement and high cumulative, often nephrotoxic doses of amphotericin B. A 50-year-old woman with RCM was treated successfully with amphotericin B lipid complex as primary therapy. The patient previously had displayed progressive intracranial involvement and rising serum creatinine levels while receiving the conventional (nonlipid) form of amphotericin B. A literature review identified only a few cases where systemic antifungal therapy was administered, with minimal or no surgery. Our case further supports that amphotericin B lipid complex can be used as primary therapy in selected patients with RCM, without the need for surgical exenteration.

Original languageEnglish (US)
Pages (from-to)519-526
Number of pages8
JournalPharmacotherapy
Volume22
Issue number4
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review'. Together they form a unique fingerprint.

  • Cite this

    Mondy, K. E., Haughey, B., Custer, P. L., Wippold, F. J., Ritchie, D. J., & Mundy, L. M. (2002). Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: Case report and literature review. Pharmacotherapy, 22(4), 519-526. https://doi.org/10.1592/phco.22.7.519.33679